Mostrar el registro sencillo del ítem
Efecto de la cúrcuma sobre características fenotípicas de la cepa mutante de Caenorhabditis elegans NL5901 para la enfermedad de Parkinson
dc.contributor.advisor | Sanchez Mora, Ruth Melida | |
dc.contributor.author | Fajardo Rusinque, Angie Fernanda | |
dc.date.accessioned | 2022-03-09T17:10:15Z | |
dc.date.available | 2022-03-09T17:10:15Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | https://repositorio.unicolmayor.edu.co/handle/unicolmayor/4793 | |
dc.description.abstract | La enfermedad de Parkinson EP es la segunda enfermedad neurodegenerativa más común, es primordialmente una enfermedad relacionada con la edad, afectando típicamente a personas sobre los sesenta años. Aunque, no tiene una etiología definida existen procesos bilógicos similares en los pacientes. Entre estos, el aumento del estrés oxidativo, la pérdida selectiva y temprana de neuronas dopaminérgicas en la Substancia Nigra y la formación de los cuerpos de Lewy. Los cuerpos de Lewy están compuestos por la acumulación de la alfasinucleina, una proteína fisiológica que se pliega de forma patológica en la EP. Un modelo para el estudio de la EP es el nematodo Caenorhabditis elegans (C elegans). Para la evaluación de la agregación proteica de alfa sinucleina existe la cepa NL5901, la cual expresa un gen que promueve la acumulación de alfasinucleina acompañada por YPF una proteína amarilla fluorescente que permite su observación. Múltiples estudios afirman que las moléculas antioxidantes tienen la capacidad de reducir agregados proteicos. Es por esto que este estudio usó la cúrcuma, un poderoso antioxidante, para demostrar el efecto que tiene sobre los agregados proteicos y el cambio en características fenotípicas del nematodo, como longevidad, reproducción y movilidad. La cepa NL5901 fue sometida a varias concentraciones de solución de cúrcuma. Donde se demostró que, el tratamiento de la cúrcuma disminuye significativamente la agregación proteica, efecto que es directamente proporcional a la concentración a la cual el nematodo es sometido, y que mejora las características fenotípicas como longevidad, reproducción y movilidad del nematodo. | spa |
dc.description.tableofcontents | TABLA DE CONTENIDO RESUMEN 12 INTRODUCCIÓN 13 1. OBJETIVOS 15 1.1 Objetivo general 15 1.2 Objetivos específicos 15 2. ANTECEDENTES 16 3. MARCO TEORICO 21 3.1 Enfermedad de Parkinson EP 21 3.1.2 Generalidades y Epidemiologia 21 3.1.3 Etiología y componente genético 22 3.1.4 Alfa Sinucleina 23 3.1 Caenorhabditis elegans 26 3.1.2 Sistema digestivo de C. elegans 28 3.1.3 Sistema nervioso 29 3.1.4 Sistema muscular 31 3.1.5 Sistema reproductor 32 3.1.6 Ciclo de vida 33 3.2 Caenorhabditis elegans y la enfermedad de Parkinson 35 3.3 Estrés Oxidativo 38 3.4 Cúrcuma 38 4 DISEÑO METODOLÓGICO 42 4.1 Tipo de estudio y población 42 4.2 Hipótesis 42 4.3 Procedimientos y técnicas 42 4.3.2 Preparación del NGM y condiciones de cultivo 42 4.3.3 Preparación de solución de la cúrcuma 43 4.3.4 Sincronización por medio del tratamiento con hipoclorito 43 4.3.5 Concentración Mínima Inhibitoria 44 4.3.6 Fenotipifícacion de las cepas de C. elegans NL5901y N2 44 4.3.7 Evaluación estadística de los datos obtenidos 46 5 RESULTADOS 49 5.1 Estadios Larvarios y diferencias fenotípicas de las cepas N2 y NL5901 49 5.2 Evaluación del efecto de la cúrcuma sobre la longevidad de la cepa NL5901 de C elegans 55 5.3 Evaluación del efecto de la cúrcuma sobre la movilidad de la cepa NL5901 de C elegans 56 5.4 Evaluación del efecto de la cúrcuma sobre la reproducción de la cepa NL5901 de C elegans 57 5.5 Evaluación del efecto de la cúrcuma sobre la agregación proteica de la cepa NL5901 de C elegans 59 6 DISCUSIÓN 61 7 CONCLUSIONES 64 8 REFERENCIAS 65 9 ANEXOS 69 | spa |
dc.format.extent | 74p. | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.publisher | Universidad Colegio Mayor de Cundinamarca | spa |
dc.rights | Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2018 | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0/ | spa |
dc.title | Efecto de la cúrcuma sobre características fenotípicas de la cepa mutante de Caenorhabditis elegans NL5901 para la enfermedad de Parkinson | spa |
dc.type | Trabajo de grado - Pregrado | spa |
dc.description.degreelevel | Pregrado | spa |
dc.description.degreename | Bacteriólogo(a) y Laboratorista Clínico | spa |
dc.identifier.barcode | 58441 | |
dc.publisher.faculty | Facultad de Ciencias de la Salud | spa |
dc.publisher.place | Bogotá D.C | spa |
dc.publisher.program | Bacteriología y Laboratorio Clínico | spa |
dc.relation.references | Goetz CG. The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. Cold Spring Harbor Perspectives in Medicine:. 2011;1(1):a008862. | spa |
dc.relation.references | Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2(7):492-501. | spa |
dc.relation.references | Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. The American Journal of Pathology. 1998;152(4):879-84. | spa |
dc.relation.references | Chen X, Barclay JW, Burgoyne RD, Morgan A. Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases. Chem Cent J. 2015;9 | spa |
dc.relation.references | Van Ham TJ, Thijssen KL, Breitling R, Hofstra RMW, Plasterk RHA, Nollen EAA. C. elegans Model Identifies Genetic Modifiers of α-Synuclein Inclusion Formation During Aging. PLOS Genetics. 2008;4(3):e1000027. | spa |
dc.relation.references | Xiao L, Li H, Zhang J, Yang F, Huang A, Deng J, et al. Salidroside protects Caenorhabditis elegans neurons from polyglutamine-mediated toxicity by reducing oxidative stress. Molecules. 2014;19(6):7757-69 | spa |
dc.relation.references | Liu J, Banskota AH, Critchley AT, Hafting J, Prithiviraj B. Neuroprotective effects of the cultivated Chondrus crispus in a C. elegans model of Parkinson's disease. Mar Drugs. 2015;13(4):2250-66. | spa |
dc.relation.references | Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem. 2006;97(1):105-15. | spa |
dc.relation.references | Shen LR, Parnell LD, Ordovas JM, Lai CQ. Curcumin and aging. BioFactors. 2013;39(1):133-40. | spa |
dc.relation.references | Harish G, Venkateshappa C, Mythri RB, Dubey SK, Mishra K, Singh N, et al. Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson's disease. Bioorg Med Chem. 2010;18(7):2631-8. | spa |
dc.relation.references | Khuwaja G, Khan MM, Ishrat T, Ahmad A, Raza SS, Ashafaq M, et al. Neuroprotective effects of curcumin on 6-hydroxydopamine-induced Parkinsonism in rats: behavioral, neurochemical and immunohistochemical studies. Brain Research. 2011;1368:254-63 | spa |
dc.relation.references | Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 2008;115(4):479-89. | spa |
dc.relation.references | Liu Z, Yu Y, Li X, Ross CA, Smith WW. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacological Research. 2011;63(5):439-44. | spa |
dc.relation.references | Nussbaum RL, Ellis CE. Alzheimer's Disease and Parkinson's Disease. New England Journal of Medicine. 2003;348(14):1356-64. | spa |
dc.relation.references | Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol. 2013;11(4):338-78. | spa |
dc.relation.references | Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. Cmaj. 2016;188(16):1157-65. | spa |
dc.relation.references | Marjama-Lyons JM, Koller WC. Parkinson's disease. Update in diagnosis and symptom management. Geriatrics. 2001;56(8):24-5, 9-30, 3-5. | spa |
dc.relation.references | Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends in Neurosciences. 2010;33(12):559-68 | spa |
dc.relation.references | Chartier-Harlin M-C, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. α-synuclein locus duplication as a cause of familial Parkinson's disease. The Lancet. 2004;364(9440):1167-9. | spa |
dc.relation.references | Burre J. The Synaptic Function of alpha-Synuclein. J Parkinsons Dis. 2015;5(4):699-713. | spa |
dc.relation.references | Xu L, Pu J. Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application. 2016;2016:1720621. | spa |
dc.relation.references | Fink VNUALFAL. Protein misfolding, aggregation and conformational Diseases. . Fink VNUALFAL, editor: Springer US 2007 | spa |
dc.relation.references | Chege PM, McColl G. Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease. Frontiers in Aging Neuroscience. 2014;6:89. | spa |
dc.relation.references | Bodhicharla RK. Transgenic nematodes as a model for Parkinson’s disease. United Kinddom: University of Nottingham 2012. | spa |
dc.relation.references | Sato K, Norris A, Sato M, Grant BD. C. elegans as a model for membrane traffic. WormBook : the online review of C elegans biology [Internet]. 2014 2014/04//:[1-47 pp.]. Available from: http://europepmc.org/abstract/MED/24778088 https://doi.org/10.1895/wormbook.1.77.2 | spa |
dc.relation.references | Book W. Caenorhabditis elegans as a genetic organism. In: book H, editor. Anatomy 2014. | spa |
dc.relation.references | Asan A, Raiders SA, Priess JR. Morphogenesis of the C. elegans Intestine Involves Axon Guidance Genes. PLoS Genet. 2016;12(4):e1005950. | spa |
dc.relation.references | C elegans feeding [Internet]. WormBook : the online review of C. elegans biology. 2005. | spa |
dc.relation.references | Nicolas D, Lindy H-D, James D, Vincent OC, Robert JW. Caenorhabditis elegans Feeding Behaviors | spa |
dc.relation.references | University SF. C elegans nervous system In: sciences DoB, editor. Publications 2008. | spa |
dc.relation.references | Gieseler K QH, Benian GM. . Development, structure, and maintenance of C. elegans body wall muscle. In: WormBook, editor. 2005 | spa |
dc.relation.references | Bargmann CI. Chemosensation in C elegans WormBook : the online review of C elegans biology. 2006(6). | spa |
dc.relation.references | Database JSE. C. elegans Development and Reproduction. Biology I: yeast, Drosophila and C elegans: JoVe; 2018. | spa |
dc.relation.references | Maulik M, Mitra S, Bult-Ito A, Taylor BE, Vayndorf EM. Behavioral Phenotyping and Pathological Indicators of Parkinson's Disease in C. elegans Models. Frontiers in Genetics. 2017;8:77. | spa |
dc.relation.references | Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-11. | spa |
dc.relation.references | Harrington AJ, Hamamichi S, Caldwell GA, Caldwell KA. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. Dev Dyn. 2010;239(5):1282-95. | spa |
dc.relation.references | Bharat B. Aggarwal Y-JS, Shishir Shishodia. The molecular targets and therappeutic uses of curcumin in health and disease.: Springer; 2007. 501 p. | spa |
dc.relation.references | Porta-de-la-Riva M, Fontrodona L, Villanueva A, Ceron J. Basic Caenorhabditis elegans methods: synchronization and observation. J Vis Exp. 2012(64):e4019. | spa |
dc.relation.references | Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. Journal of Pharmaceutical Analysis. 2016;6(2):71- 9 | spa |
dc.relation.references | Park HH, Jung Y, Lee SV. Survival assays using Caenorhabditis elegans. Mol Cells. 2017;40(2):90-9. | spa |
dc.relation.references | Chen Z, Sun D, Bi X, Zeng X, Luo W, Cai D, et al. Pharmacokinetic based study on "lagged stimulation" of Curcumae Longae Rhizoma - Piper nigrum couplet in their main active components' metabolism using UPLC-MS-MS. Phytomedicine. 2017;27:15-22 | spa |
dc.relation.references | Peng S, Li Z, Zou L, Liu W. Improving curcumin solubility and bioavailability by encapsulation in saponin-coated curcumin nanoparticles prepared using a simple pH-driven loading method. 2018. | spa |
dc.relation.references | Tyagi P, Singh M, Kumari H, Kumari A, Mukhopadhyay K. Bactericidal activity of curcumin I is associated with damaging of bacterial membrane. PLoS One. 2015;10(3):e0121313 | spa |
dc.relation.references | Yedlapudi D, Joshi GS, Luo D, Todi SV, Dutta AK. Inhibition of alphasynuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Scientific Reports. 2016;6:38510. | spa |
dc.relation.references | Dauer W, Przedborski S. Parkinson's Disease: Mechanisms and Models. Neuron. 2003;39(6):889-909. | spa |
dc.relation.references | Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha - Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(16):10813-8 | spa |
dc.relation.references | Pestov NB, Shakhparonov MI, Kornienko TV. [Matricide in Caenorhabditis elegans as an example of programmed death of whole animal organism: role of mitochondrial oxidative stress]. Bioorg Khim. 2011;37(5):705-10. | spa |
dc.relation.references | ;132(10):480-7. 59. Li Q, Zhang SH, Yu YH, Wang LP, Guan SW, Li PF. Toxicity of sodium fluoride to Caenorhabditis elegans. Biomed Environ Sci. 2012;25(2):216-23. | spa |
dc.rights.accessrights | info:eu-repo/semantics/closedAccess | spa |
dc.rights.creativecommons | Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) | spa |
dc.subject.lemb | Investigación | |
dc.subject.lemb | Enfermedad | |
dc.subject.proposal | Caenorhabditis elegans | spa |
dc.subject.proposal | Cúrcuma | spa |
dc.subject.proposal | Enfermedad de Parkinson | spa |
dc.subject.proposal | Alfa sinucleina | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_7a1f | spa |
dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.type.content | Text | spa |
dc.type.driver | info:eu-repo/semantics/bachelorThesis | spa |
dc.type.redcol | https://purl.org/redcol/resource_type/TP | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dc.rights.coar | http://purl.org/coar/access_right/c_14cb | spa |